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Aims Atrial fibrillation (AF) produces a hypercoagulable state. Stimulation of protease-activated receptors by coagulation
factors provokes pro-fibrotic, pro-hypertrophic, and pro-inflammatory responses in a variety of tissues. We studied
the effects of thrombin on atrial fibroblasts and tested the hypothesis that hypercoagulability contributes to the devel-
opment of a substrate for AF.
Methods
and results
In isolated rat atrial fibroblasts, thrombin enhanced the phosphorylation of the pro-fibrotic signalling molecules Akt and
Erk and increased the expression of transforming growth factor b1 (2.7-fold) and the pro-inflammatory factor mono-
cyte chemoattractant protein-1 (6.1-fold). Thrombin also increased the incorporation of 3H-proline, suggesting en-
hanced collagen synthesis by fibroblasts (2.5-fold). All effects could be attenuated by the thrombin inhibitor
dabigatran. In transgenic mice with a pro-coagulant phenotype (TMpro/pro), the inducibility of AF episodes lasting
.1 s was higher (7 out of 12 vs. 1 out of 10 in wild type) and duration of AF episodes was longer compared with
wild type mice (maximum episode duration 42.8+ 68.4 vs. 0.23+ 0.39 s). In six goats with persistent AF treated
with nadroparin, targeting Factor Xa-mediated thrombin generation, the complexity of the AF substrate was less pro-
nounced than in control animals (LA maximal activation time differences 23.3+3.1 ms in control vs. 15.7+2.1 ms in
nadroparin, P, 0.05). In the treated animals, AF-induced a-smooth muscle actin expression was lower and endomysial
fibrosis was less pronounced.
Conclusion The hypercoagulable state during AF causes pro-fibrotic and pro-inflammatory responses in adult atrial fibroblasts.
Hypercoagulability promotes the development of a substrate for AF in transgenic mice and in goats with persistent
AF. In AF goats, nadroparin attenuates atrial fibrosis and the complexity of the AF substrate. Inhibition of coagulation
may not only prevent strokes but also inhibit the development of a substrate for AF.
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Translational perspective
This article describes experimental evidence for the fact that hypercoagulability—as caused by atrial fibrillation—induces pro-fibrotic and
pro-inflammatory responses in adult atrial fibroblasts, that transgenic mice with hypercoagulability are more susceptible to atrial fibrillation
than wild-type mice, and that the inhibition of hypercoagulability can partially prevent atrial remodelling in a well-characterized animal mod-
el of AF. These data show that the traditional causality of AF causing hypercoagulability may also hold in the opposite direction, i.e. that
hypercoagulability has the potential to cause or promote AF. If confirmed in human studies, this new paradigm may have consequences
for anticoagulant therapy in patients with or at risk for AF.
Introduction
While the observation that atrial fibrillation (AF) causes activation of
blood coagulation has been made decades ago, far less is known
about the effect of activated blood coagulation on atrial remodelling
and on the progression of AF. The discovery of protease-activated
receptors (PARs) in the early 1990s and the identification of mul-
tiple coagulation proteases (i.e. clotting factors) as their main natural
ligands triggered intense research on non-haemostatic functions of
the coagulation cascade.1 –3 It was demonstrated that activation of
PARs by coagulation factors can cause vascular alterations, pro-
fibrotic effects, and inflammation.1 –3
Protease-activated receptors belong to the transmembrane G
protein-coupled receptors superfamily and are expressed in many
different cell types throughout the body.4,5 The four isoforms
(PAR1 to PAR4) differ in their expression levels in various cell types
and their downstream signalling.6 PAR1 and PAR2 are the most im-
portant isoforms in the heart.7 Thrombin, an important effector of
the coagulation cascade, can activate PAR1, PAR3, and PAR4, while
Factor Xa mainly activates PAR1 and PAR2.
PAR1 is expressed in myocytes, fibroblasts, endothelial cells,
and smooth muscle cells.4 Its expression is elevated in left ventri-
cular tissue from patients with ischaemic heart disease or heart
failure.8,9 PAR1 activation leads to myocyte hypertrophy6,7 and pro-
liferation of fibroblasts.10,11 Mice overexpressing PAR1 develop car-
diac hypertrophy and dilated cardiomyopathy.12 In contrast, PAR1
deficiency was protective in a mouse model of ischaemia–
reperfusion.12
PAR2 is expressed by myocytes, smooth muscle cells, and endo-
thelial cells, but its expression by fibroblasts is uncertain.4 In myo-
cytes, PAR2 activation leads to mitogen-activated protein kinase
activation and cellular hypertrophy.7 PAR2 deficiency leads to
reduced infarct sizes in ischaemia–reperfusion models and reduces
inflammatory responses.8
Outside the heart, an important role of PARs has been implicated
in many fibro-proliferative diseases such as fibrosis of skin, lung,
and liver.13 – 15 It is so far unclear to what extent PAR activation
by the coagulation system could contribute to fibrosis in the heart.
As inflammatory changes, tissue fibrosis, and cellular hypertrophy
significantly contribute to loss of electrical conductivity between
myocytes and thus conduction disturbances in dilated and fibrillating
atria,16 we hypothesize that the hypercoagulable state during
AF promotes structural remodelling in the atria and contributes
to the development of a substrate for AF by PAR activation. We
aimed to investigate whether activated coagulation factors induce
fibroblast remodelling, whether hypercoagulability enhances the
inducibility and stability of AF episodes in transgenic mice, and
whether nadroparin, targeting Factor Xa and thrombin, inhibits
the development of a substrate for AF in goats.
Materials and methods
Isolation and culture of adult rat atrial
fibroblasts
Atria of adult rats were excised and placed in ice-cold Krebs Henseleit
buffer. The tissue was minced into small pieces and digested with
0.15 mg/mL Liberase TM (Roche Diagnostics GmbH, Mannheim,
Germany). Cells from the digestions were pooled, filtered, and centri-
fuged. The pellet was resuspended in Dulbecco’s modified Eagle’s me-
dium (DMEM; Lonza, Verviers, Belgium) with 10% foetal calf serum
(FCS) and penicillin–streptomycin (50 U/mL and 50 mg/mL, respective-
ly) (Invitrogen Corporation, Breda, The Netherlands) and seeded on
uncoated dishes.17,18 On the next day, non-adherent cells were
removed by washing with phosphate buffered saline (PBS). Cells were
cultured at 378C under 5% CO2 in DMEM with 10% FCS and 1%
penicillin–streptomycin (50 U/mL and 50 mg/mL, respectively) (Invitro-
gen Corporation, Breda, The Netherlands). At confluence, cells were
split using 0.05% trypsin-ethylenediaminetetraacetic acid (Life technolo-
gies, Bleiswijk, The Netherlands) and cultured again until confluence was
reached. After this step, cells were trypsinized, counted, and seeded at a
density of 15 000 cells/cm2. On the next day, cells were serum starved
for 24 h before experiments were carried out. Cells showed positive
staining for vimentin (Santa Cruz Biotechnology, Heidelberg, Germany)
and prolyl 4-hydroxylase subunit beta (P4HB, Novus Biologicals,
Littleton, CO, USA), and part of the cells were positive for smooth mus-
cle actin (Dako, Heverlee, Belgium), indicative of differentiation towards
myofibroblasts. Less than 5% of the cells were negative for P4HB.
Cell stimulation with thrombin
Cells were exposed to 1025 units/mL up to 0.5 units/mL thrombin from
human plasma (Diagnostica Stago S.A.S., Asnie`res sur Seine, France) for
5 min up to 24 h. Dabigatran (Boehringer Ingelheim) at a final concen-
tration of 350 ng/mL was added 30 min before the addition of thrombin.
The dabigatran concentration was based on approximately two times
the maximum plasma concentration in patients and the concentration
required to reduce in vitro plasma thrombin generation by 50% (data
not shown). To investigate whether the responses induced via thrombin
were mediated by PAR1, we used PAR1 antagonists, 30–100 mM
RWJ56110 (Tocris Bioscience, Bristol, UK) and 1 mM SCH79797 dihy-
drochloride (Tocris Bioscience, Bristol, UK). Furthermore, the PAR1
blocking antibody ATAP2 (Santa Cruz Biotechnology, Heidelberg,
Germany) was used at 10 mg/mL. The PAR1 receptor agonist Trap-14
(Bachem, Bubendorf, Switzerland) was used as a positive control.
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Western blots
Proteins from whole cell lysates were isolated using radioimmuno-
precipitation assay buffer (0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), and 1% Igepal ca-630 in Tris-buffered saline).
After denaturation at 998C for 5 min, proteins were separated by
SDS-polyacrylamide gel, transferred to polyvinylidene difluoride mem-
branes (Bio-Rad, Veenendaal, The Netherlands) and blocked with 5%
milk. Blots were incubated with antibodies against phospho-Erk (E-4)
(Santa Cruz Biotechnology, Heidelberg, Germany), phospho-Akt
(Ser473) (D9E), or phospho-p38 (Thr180/Tyr182) (both Cell Signaling
Technology, Danvers, MA, USA). The membranes were stripped (strip-
ping buffer containing 2% SDS, 100 mM b-mercaptoethanol, and
62.5 mM Tris buffer) for 30 min at 558C, washed, and incubated with
the corresponding antibody detecting the total protein amount, i.e. total
p44/42 MAPK (Erk1/2) (137F5) and Akt (C67E7) and p38 (all three Cell
Signalling Technology, Danvers, MA, USA). After that, membranes were
reprobed with GAPDH antibodies (Fitzgerald Industries International,
Acton, MA, USA). Signals were detected using enhanced chemilumines-
cence (Perkin Elmer, Waltham, MA, USA) and quantified by densitom-
etry. Protein levels were expressed relative to the respective control
group of each experiment.
Real-time quantitative polymerase chain
reaction
Total RNA isolated using the Nucleospin II kit (Macherey-Nagel, Du¨ren,
Germany) was converted to cDNA by the QuantiTect Reverse Tran-
scription kit (Qiagen, Venlo, The Netherlands). Gene expression was
measured with Absolute QPCR SYBR Green ROX Mix (Abgene,
Epsom, UK) in the presence of 7.5 ng cDNA and 200 nM forward and
reverse primers. Real-time quantitative PCR was performed on a
Bio-Rad CFX384 cycler. The initial denaturation and activation of the
DNA polymerase (958C for 3 min) was followed by 35 cycles with de-
naturation for 15 s at 958C and annealing and elongation for 30 s at
608C, followed by a melt curve. Gene expression levels were corrected
for ribosomal protein P0 (36b4) reference gene expression, and values
were expressed relative to the respective control group of each experi-
ment. Primers used are shown in Table 1.
Proline incorporation
Cells were grown in 12-well plate and serum starved for 24 h.
L-[2,3,4,5-3H]Proline (Perkin Elmer, Groningen, The Netherlands) was
added to all wells at a concentration of 1 mCi/mL directly after adding
thrombin. Cells were cultured for an additional 24 h. Thereafter, cells
were washed twice with PBS, and proteins were solubilized with
0.5 M NaOH for 1 h at room temperature. Proteins were collected
in scintillation tubes, and 4 mL of Ultima Gold XR scintillation liquid
(Perkin Elmer, Groningen, The Netherlands) was added. The amount
of radioactivity was determined by a LS6500 Beckman counter.
Immunofluorescence and proliferation
Cells were fixated in 4% paraformaldehyde for 10 min on ice and
washed with PBS. Proliferaton was detected using the CyQuant cell pro-
liferation assay kit (Invitrogen–Molecular Probes, Eugene, OR, USA).
To confirm fibroblast phenotype, a counter staining with P4HB was
performed.
Inducibility and stability of atrial fibrillation
in transgenic mice with enhanced thrombin
activity
TMpro/pro mice carry a thrombomodulin (TM) gene mutation which
causes diminished generation of activated protein C (APC),19 resulting
in a hypercoagulable phenotype.20 Adult mice [wild type (WT), n ¼ 10,
weight 24.9+ 4.5 g; and TMpro/pro, n ¼ 12, weight 24.2+ 2.2 g] were
anaesthetized by inhalation of 2% isoflurane through a nose cone. An
octapolar catheter (CIBer, NuMed Inc., Hopkinton, NY, USA) was in-
serted in the oesophagus and connected to a stimulus isolation unit.
At an output of two times threshold, pacing protocols were applied
to determine the sinus node recovery time [interval from the last stimu-
lus of a train of 40 stimuli with a basic cycle length (BCL) of 100 ms to
the onset of the first subsequent P wave] and atrioventricular Wenck-
ebach cycle length (AV Wenck, first cycle length where 1:1 conduction
to the ventricles was lost when the BCL was decreased from 100 ms by
steps of 2 ms). Atrial fibrillation inducibility was tested by applying 5 s
trains of stimuli with a cycle length starting at 60 ms and decreased by
2 ms for each successive train. Atrial fibrillation was defined as a rapid
irregular atrial rhythm with an irregular ventricular response lasting
longer than 1 s. Atrial tissues were excised, fixated in buffered 4% for-
maldehyde, and embedded in paraffin. Tissue sections of 5 mm were de-
paraffinized, rehydrated, and stained with Sirius red for collagen depos-
ition. Photographs were taken at ×100 magnification, and collagen
staining was quantified using ImageJ analysis software.
Effect of nadroparin treatment on the
development of an atrial fibrillation
substrate in goats
In 15 female goats, an atrial endocardial pacemaker lead (Medtronic
Capsurefixw) was implanted in the right atrial appendage and connected
to an implantable neurostimulator (Medtronic Itrelw). Atrial fibrillation
was maintained by repetitive 50 Hz burst pacing at three times thresh-
old. Six goats were treated with subcutaneous injections of 150 IU/kg of
the low molecular weight heparin nadroparin twice daily during the en-
tire AF stimulation period. Nine untreated animals served as controls.
After 4 weeks of AF, an open chest experiment was performed. Animals
were anaesthetized with sufentanyl (6 mg/kg/h), midazolam (0.8 mg/kg/h),
and pancuronium (0.3 mg/kg/h). After left-sided thoracotomy, mapping
was performed as described recently.21 Left and right AF electrograms
were recorded for 30 s in each animal using a spoon-shaped epicardial
mapping electrode (12.8 cm2, 2.4 mm inter-electrode distance). A silver
plate in the thoracic cavity served as indifferent electrode. Unipolar signals
were recorded using a custom-made 256-channel mapping amplifier
(bandwidth 0.1–408 Hz, sampling rate 1 kHz, resolution 16 bits) and
stored for offline analysis. Thereafter, left and right atrial biopsies were
taken for histological analysis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Primers
Gene Forward Reverse
36b4 gttgcctcagtgcctcactc gcagccgcaaatgcagatgg
IL6 aacagcgatgatgcactgtc tccaggtagaaacggaactc
MCP-1 ccgactcattgggatcatctt tgtctcagccagatgcagttaat
PAR1 ttcctggcagtggtgtaccc cgtggcaggtggtgatgttg
PAR2 tgggaggtatcacccttctg gcgtgtccaatctgccaatc
PAR3 gggttaggctgctgtttctg tagttgtggtggctcctgtc
PAR4 atgctcgggttcagcatcag cctcgtggattaggcttgtc
Smooth muscle actin caccatcgggaatgaacg tgcctgggtacatggtag
TGFb1 aagaagtcacccgcgtgcta tgtgtgatgtctttggttttgtca
IL6, interleukin-6; MCP-1, monocyte chemotactic protein-1; PAR,
protease-activated receptor; TGFb1, transforming growth factor b1.
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Local activation times were identified as points of maximum negative
dV/dt in each unipolar electrogram. Fibrillation waves were defined as
areas surrounded by lines of block or fusion everywhere along their
boundaries within the mapping array as described earlier.22,23 To quan-
tify AF complexity, we calculated the maximal activation time differ-
ences in each AF beat and the unipolar fractionation index as
described previously.24
Thrombin generation in goat plasma
Thrombin generation in goat plasma was measured using the calibrated
automated thrombogram (Thrombinoscope B.V., Maastricht, The
Netherlands) using platelet-poor plasma using final concentrations of
1 pM tissue factor and 4 mM phospholipids.25 To correct for inner-filter
effects and substrate consumption, the results from each thrombin gen-
eration analysis were calibrated against the fluorescence curve obtained
from the same plasma with a fixed amount of calibrator (Thrombin Cali-
brator, Thrombinoscope B.V., Maastricht, The Netherlands). Fluores-
cence was measured in an Ascent Reader (Thermolabsystems OY,
Helsinki, Finland) equipped with a 390/460 nm filter set, and thrombin
generation curves were calculated using Thrombinoscope software
(Thrombinoscope B.V., Maastricht, The Netherlands). All coagulation
measurements were performed in triplicate.
Histology
After the electrophysiological studies in goats, hearts were excised, and
tissue samples were fixated in buffered 4% formaldehyde, and embedded
in paraffin for histological evaluation. Tissue sections of 5 mm were
de-paraffinized, rehydrated, and stained with haematoxylin and eosin.
Photographs were taken at×400 magnification. In each goat, the diameter
of the atrial myocytes was measured in 30–35 myocytes, with the nucleus
in plane of the section. Endomysial fibrosis was defined as connective
tissue separating individual myocytes within bundles. The width of endo-
mysial tissue septa was quantified as the smallest distance between myo-
cytes within bundles. ImageJ 1.37a (National Institute of Health, USA) was
used for analysis.
Staining for matrix metalloproteinase-1 (MMP-1) and for tissue inhibi-
tor of matrix metalloproteinase-1 (TIMP-1) was performed on frozen
tissue sections with antibodies obtained from Bio-Connect Diagnostics
(Huissen, The Netherlands) and for transforming growth factor b1
(TGFb1; Santa Cruz Biotechnology, TX, USA) using a tyramide-FITC
enhancement step as described.26 Whole mount images were made
with a ×20 objective using an automated slide scanner (3D-Histech,
Budapest, Hungary). Whole mount images were generated with the
program Pannoramic Viewer (3D-Histech, Boedapest, Hungary), and
staining was quantified using ImageJ.
To quantify the number of myofibroblasts, a-smooth muscle actin
(aSMA, Thermo Scientific, Rockford, IL, USA) staining was performed
as described above. For visualization of the relatively small myofibro-
blasts, from each section at least three images were generated at higher
magnification (×20; in total×400) using Pannoramic Viewer.a-Smooth
muscle actin-positive vascular smooth muscle cells of the larger vessels
were manually excluded from the analysis by applying a maximal thresh-
old in the analysis program ImageJ. Results were expressed as percent-
age of positive area per image.
All animal studies were conducted in accordance with national and
institutional guidelines for the use of laboratory animals and were ap-
proved by the local ethics committees for animal experiments of the
Universities in Groningen or Maastricht.
Statistics
Data are expressed as mean values+ standard deviation. Comparisons
between two groups were done using a Student’s t-test, and
comparisons between multiple groups were done using one-way ana-
lysis of variance (ANOVA) with post hoc Dunnett correction. If para-
meters were investigated in both right and left atria, a two-way
ANOVA was used. Two-sided P-values of ,0.05 were considered stat-
istically significant. Statistical analyses were performed using Graphpad
Prism 6 for Mac OS X (Graphpad Software Inc.).
Results
Effects of thrombin on pro-fibrotic
and pro-inflammatory pathways
Real-time PCR confirmed the presence of PAR1 mRNA in adult at-
rial fibroblasts. PAR2 and PAR3 mRNA expressions were at least
10-times lower (based on the number of PCR cycles required for
the detection of the respective mRNAs), and PAR4 mRNA could
not be detected in these cells.
Five minutes exposure of atrial fibroblasts to thrombin was suffi-
cient to induce phosphorylation of the PAR signalling molecules Akt,
Erk, and p38 (Figure 1). Incubation with dabigatran inhibited phos-
phorylation of these signalling molecules.
Thrombin exposure for 24 h increased mRNA levels of
interleukin-6 (Figure 2A) and monocyte chemotactic protein-1
(MCP-1) (Figure 2B) in atrial fibroblasts. Thrombin also increased
mRNA expression of aSMA (Figure 3A), which is indicative of dif-
ferentiation towards active myofibroblasts. In addition, expression
of TGFb1 (Figure 3B) was increased. 3H-proline incorporation
(Figure 3C) was dose-dependently increased with thrombin, indicat-
ing increased collagen production. Again, dabigatran attenuated all
these effects.
Pro-inflammatory and pro-fibrotic
effects of thrombin are mediated
by protease-activated receptor-1
Figure 4A shows the effect of PAR1 receptor antagonists on the
thrombin-induced increase in 3H-proline incorporation in atrial
fibroblasts. The PAR1 receptor antagonists, RWJ56110 and
SCH79797, and ATAP-2, a PAR1 blocking antibody, strongly attenu-
ated the effect of thrombin on 3H-proline incorporation. Vice versa,
Trap-14, a PAR1 agonist, strongly increased the incorporation of
3H-proline. This effect was inhibited by RWJ56110, SCH79797,
and ATAP-2. Trap-14 enhanced gene expression of TGFb1,
aSMA, and MCP-1 to a similar extent as thrombin (Figure 4B). These
data suggest that the response induced by thrombin is mediated
by PAR1 activation. In addition, PAR1 mRNA expression was up-
regulated when the cells were stimulated with thrombin (Figure 4C),
indicating a positive feedback up-regulation of PAR1 induced by its
stimulation with thrombin. The same response was found for the iso-
forms PAR2 and PAR3 (Figure 4D and E). However, the expression
level of PAR2 and PAR3 was far lower than for PAR1. Dabigatran at-
tenuated the response of the PARs on thrombin exposure.
Thrombin does not induce fibroblast
proliferation
Thrombin did not induce proliferation, i.e. an increase in cell number
of atrial fibroblasts. In contrast, FCS (positive control) did induce
proliferation (Figure 5).
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Figure 1 Thrombin induces phosphorylation of Erk (n ¼ 6–7), Akt (n ¼ 7–8), and p38 (n ¼ 5–6). Dabigatran attenuated these effects.
*P, 0.05 compared with control; #P, 0.05 compared with thrombin only; §P, 0.05 compared with dabigatran control.
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Inducibility and stability of atrial
fibrillation in transgenic mice with
enhanced thrombin activity
Mice with a hypercoagulable phenotype (TMpro/pro) showed similar
electrocardiogram intervals and indicators for SA and AV node func-
tion when compared with WT mice (Figure 6A, left and right panels,
respectively). However, burst pacing evoked episodes of AF lasting
longer than 1 s in a significantly larger proportion of TMpro/pro mice
than in WT mice, and the duration of the longest AF episode ob-
served in each mouse was also significantly longer in TMpro/pro
mice (Figure 6C, example in Figure 6B). Enhanced inducibility of AF
in the TMpro/pro mice was associated with increased collagen depos-
ition in atria of the heart (Figure 6D). Compared with WT mice
(0.078%+ 0.025), collagen area coverage was six-fold higher in
TMpro/pro mice (0.457%+ 0.114, P ¼ 0.0182).
Nadroparin inhibits the development
of an atrial fibrillation substrate in goats
In goats with AF, the effect of treatment with nadroparin, targeting
Factor Xa, and thrombin on the remodelling process was investi-
gated. Before induction of AF, tissue factor-induced thrombin gen-
eration was 152+ 23 nM*min in goat plasma. After 4 weeks of AF,
tissue factor-induced thrombin generation had increased to 252+
44 nM*min confirming that 4 weeks of AF induces hypercoagulabil-
ity in goats. Nadroparin treatment decreased thrombin generation
by 75% demonstrating substantial inhibition of coagulation.
After 4 weeks of AF, a protective effect of nadroparin treatment
was clearly detectable (Figure 7). The complexity of AF was lower in
the nadroparin group. Maximal activation time differences measured
with a mapping electrode (a commonly used measure for conduc-
tion heterogeneity and block)27 were significantly shorter in the na-
droparin group in both right and left atria (Figure 7A). Also, the
unipolar fractionation index was lower in the nadroparin group
(Figure 7B). There was no difference in AF cycle length between
the two groups (Table 2). The cell–cell distances, an early marker
for atrial endomysial fibrosis,22 was 50% lower in the
nadroparin group in both right and left atria (Figure 7C). Similarly,
the number of aSMA-positive myofibroblasts28 was reduced in
the treated animals (Figure 7D). The cell diameter of atrial myocytes
was not affected by nadroparin treatment (RA: ctr 15.4+3.6 mm,
nadroparin 14.1+ 2.6 mm; LA: ctr 16.9+ 3.0 mm, nadroparin
15.1+ 2.3 mm).
Anticoagulation through nadroparin not only affected AF-related fi-
brosis but influenced matrix degradation as well. Levels of MMP-1 and
its inhibitor TIMP-1, as assessed by immunohistochemical analysis,
were not significantly altered upon treatment with nadroparin. How-
ever, the difference between left and right atria (delta MMP-1) was re-
duced by a factor 9 through nadroparin administration (P ¼ 0.026).
The ratio of MMP-1 over TIMP-1 was not different between control
and anticoagulated animals for the separate left and right atria. For
the combined left and right atria, the MMP-1/TIMP-1 ratio was
80% reduced in the atria of nadroparin-treated goats (Figure 7E).
No differences were observed in TGFb1 staining between treated
and non-treated groups.
Discussion
The present study shows that thrombin induces pro-inflammatory
and pro-fibrotic effects in adult atrial fibroblasts. These effects seem
to be mediated by PAR1-receptor stimulation. Importantly, the effects
of thrombin can be inhibited by the direct thrombin inhibitor dabiga-
tran. In transgenic mice with enhanced thrombin generation due to a
thrombomodulin mutation, inducibility and stability of AF episodes as
well as atrial collagen deposition are enhanced. Finally, nadroparin
treatment, targeting Factor Xa-mediated thrombin generation, is
Figure 2 Thrombin dose-dependently increased expression of (A) interleukin-6 (n ¼ 8–13) and (B) monocyte chemotactic protein-1 (n ¼ 8–
12). Dabigatran reduced these effects. IL6, interleukin-6; MCP-1, monocyte chemoattractant protein-1. *P, 0.05 compared with control;
#P, 0.05 compared with thrombin only.
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associated with reduced complexity of the AF substrate, less endomy-
sial fibrosis, and reduced aSMA staining in a well-characterized animal
model of persistent AF. Taken together, these data suggest a role of
hypercoagulability in the development of a substrate for AF.
Thrombin elicits pro-inflammatory and
pro-fibrotic effects in atrial fibroblasts
This study demonstrates that in adult atrial fibroblasts, thrombin
elicits pro-fibrotic and pro-inflammatory effects. These data are
in line with other reports showing similar effects in fibroblasts iso-
lated from other tissues, such as kidney and lung, as well as in ven-
tricular cardiac fibroblasts, where a pro-fibrotic response upon
stimulation with thrombin has been reported earlier.29 – 32 Fur-
thermore, our data suggest that this effect is mediated by activa-
tion of PAR1 as evidenced by the facts that PAR1 is the
predominant isoform of PARs on fibroblasts, the fact that
Trap-14, a PAR1 agonist, induced a response similar to the effect
induced by thrombin, and that PAR1 blockade attenuated the in-
crease in thrombin-induced 3H-proline incorporation.
In vivo studies have demonstrated that PAR1-deficient
mice show an attenuation of inflammation and fibrosis in a
model of lung fibrosis.33 Moreover, mice deficient in PAR1 per-
formed better after ischaemia– reperfusion injury compared
with their WT littermates, although PAR1 deficiency could
not reduce infarct size.12 PAR1 antagonists were also shown to
Figure 3 Thrombin increased expression of genes associated with differentiation towards myofibroblasts and fibrosis (A) a-smooth muscle
actin (n ¼ 8–15), (B) transforming growth factor b1 (n ¼ 8–15), and increased incorporation of (C ) 3H-proline (n ¼ 4–13). Dabigatran pre-
vented these effects, except for the highest dosage of thrombin for a-smooth muscle actin and 3H-proline. *P, 0.05 compared with control;
#P, 0.05 compared with thrombin only.
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attenuate liver fibrosis and prevent LV remodelling upon
ischaemia–reperfusion in rats.15,31 In addition, PAR1 inhibition
by SCH79797 reduced infarct size in an ischaemia–reperfusion
model in rats.34
Earlier studies in neonatal fibroblasts suggested that thrombin
may stimulate fibroblast proliferation, which potentially could con-
tribute to tissue fibrosis.11 Our study was performed in adult atrial
fibroblasts and did not detect any effect of thrombin on fibroblast
Figure 4 The pro-fibrotic effect of thrombin is mediated by protease-activated receptor-1. (A) 3H-proline incorporation was reduced
with protease-activated receptor-1-specific antagonists (n ¼ 2–7). (B) 10 mM Trap-14 induced expression of pro-fibrotic genes (n ¼ 3), (C )
mRNA expression of protease-activated receptor-1 upon stimulation with thrombin (n ¼ 8–11) and the effects of concomitant incubation
with dabigatran. (D) mRNA expression of PAR2 upon stimulation with thrombin (n ¼ 4–6) and the effects of concomitant incubation with da-
bigatran. (E) mRNA expression of PAR3 upon stimulation with thrombin (n ¼ 5–6) and the effects of concomitant incubation with dabigatran.
*P, 0.05 compared with control; #P, 0.05 compared with thrombin or Trap-14 only.
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proliferation thereby confirming another study in adult cardiac fi-
broblasts that showed pro-fibrotic effects, but no effect of thrombin
on cell proliferation.32
Hypercoagulability enhances atrial
fibrillation susceptibility in transgenic
mice
To test the hypothesis that the pro-fibrotic effect of thrombin acti-
vation would quantitatively be sufficient to produce a substrate for
AF, we studied inducibility and stability of AF episodes in transgenic
mice with a pro-coagulant phenotype. The TMpro/pro mice carry a
mutation of the thrombomodulin gene leading to a reduced protein
C-mediated degradation of Factors V and VIII. The resulting activa-
tion of the coagulation system has recently been demonstrated to
aggravate the atherosclerotic phenotype in ApoE2/2 mice.20 Our
data demonstrate that in these mice, inducibility and stability of
AF as well as collagen deposition are enhanced and support the hy-
pothesis that hypercoagulability can, under certain circumstances,
produce a substrate for AF.
Nadroparin prevents the development
of an atrial fibrillation substrate in goats
In goats with AF and a hypercoagulable state resulting from AF, in-
hibition of Factor Xa-mediated thrombin generation by nadroparin
partially prevented the development of atrial fibrosis related to AF.
Along with this, the complexity of AF and the number of aSMA-
positive myofibroblasts were lower in the nadroparin-treated goats
compared with the control animals. Together with the observed
trend towards anticoagulant-induced diminished matrix degrad-
ation, as suggested by the reduced MMP-1/TIMP-1 ratio, these
data strongly support the hypothesis not only that hypercoagulabil-
ity produces atrial fibrosis during AF but also that inhibition of hy-
percoagulability may prevent the development of an AF substrate
by partially preventing atrial fibrosis. Together with our notion of
PAR1-dependent pro-fibrotic effects in atrial fibroblasts, these re-
sults suggest that the protective effect of nadroparin is due to the
inhibition of PAR1-mediated pro-fibrotic activity of activated coagu-
lation, as well as through reduced activity of proteins involved in
extracellular matrix degradation. Absence of differences in TGFb1
levels between controls and anticoagulated animals suggests that at-
tenuation of atrial fibrosis through anticoagulation may be inde-
pendent from the TGFb1 pathway.
Potential implications for anticoagulant
therapy
Until recently, patients with AF mostly received vitamin K antago-
nists (VKA) for stroke prevention. Vitamin K antagonists inhibit
proper formation of vitamin K-dependent coagulation factors (pro-
thrombin; Factors VII, IX, and X; protein C; and protein S). The pro-
teins induced by vitamin K antagonism or absence (PIVKAs)
occurring in patients on VKA therapy lack the Gla-domain, inhibiting
binding to cell membranes thereby attenuating their pro-coagulant
effects.35,36 Interestingly, membrane binding does not seem
necessary for activation of PARs by coagulation factors.37 There-
fore, the PIVKAs might still be able to activate PAR-mediated
signalling, and patients on VKA are not protected against the
pro-inflammatory and pro-fibrotic effects of PAR activation. As an
alternative for VKA, non-VKA oral anticoagulants (NOACs) have
become recommended for the prevention of stroke in patients
with AF. Non-VKA oral anticoagulants directly inhibit thrombin
(dabigatran) or Factor Xa (rivaroxaban, apixaban, edoxaban) and
could possibly inhibit both coagulation and PAR activation. There-
fore, NOACs might not only protect against stroke but may also
have the potential to inhibit atrial fibrosis and the development of
a substrate for AF. This hypothesis is further supported by the re-
cent observation by Bukowska et al. who could demonstrate
pro-inflammatory effects of activated Factor X on cultured human
atrial tissue slices. In this study, pro-inflammatory signalling and up-
regulation of the adhesion molecule ICAM-1 were prevented by
pre-exposure of the tissue slices to the Factor X antagonist rivarox-
aban.38 To the best of the authors’ knowledge, clinical studies to test
the hypothesis that NOACs but not VKAs delay the process of
structural remodelling in the atria and the progression of AF have
not been undertaken yet. It remains to be determined whether in
patients NOACs can delay the progression of AF. Whether con-
firmation of this hypothesis would lead to a broadening of the indi-
cation for anticoagulation to patients with a CHA2DS2-VASc score
of one is questionable, given the bleeding risk associated with anti-
coagulant compounds. However, the results of our study demon-
strate that PAR inhibition independently from anticoagulant
activity is a promising target for the development of new upstream
therapies for AF.
Conclusion
In summary, thrombin induced a pro-fibrotic and pro-inflammatory
response in adult atrial fibroblasts by activation of the PAR1 recep-
tors, suggesting a potential role of activated coagulation in atrial
remodelling and the development of a substrate for AF. Also, hyper-
coagulability enhanced susceptibility to AF in a transgenic mouse
Figure 5 Thrombin did not induce fibroblast proliferation
(n ¼ 3–7). *P, 0.001 compared with control.
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Figure 6 Cardiac electrophysiology in mice with a hypercoagulable phenotype. (A) Right panel: Electrocardiogram intervals in wild-type and
TMpro/pro mice (duration of the P wave, QRS duration, PQ and QT intervals). Left panel: sinus node recovery time, sinus cycle length, corrected
sinus node recovery time (¼ sinus node recovery time 2 sinus cycle length ), and AV Wenckebach cycle length. (B) Transoesophageal burst pa-
cing in a wild-type and TMpro/pro mouse. In the latter, burst pacing induced an episode of atrial fibrillation, whereas the wild-type mouse returned to
sinus rhythm immediately after the burst. (C) Inducibility of AF (episode lasting .1 s) by burst pacing (left panel) and AF episode durations (right
panel). In a significantly higher proportion of TMpro/pro mice (7 out of 12 vs. 1 out of 10), atrial fibrillation could be induced, and atrial fibrillation
episodes were significantly longer. (D) Enhanced collagen deposition (Sirius red staining) in heart atria of TMpro/pro mouse (0.457%+0.114) com-
pared with wild-type animals (0.078%+ 0.025, P ¼ 0.0182). The left picture shows a typical example of wild-type atria and the right picture of an
atria from a TMpro/pro mouse. *P, 0.05.
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Figure 7 Effect of nadroparin on the development of a substrate for atrial fibrillation. (A) Representative waves maps during atrial fibrillation in the
LA of a control goat (left) and a goat treated with nadroparin (mid panel). Complexity of atrial fibrillation quantified as maximal activation times
differences per atrial fibrillation beat was significantly lower in both LA and RA of goats treated with nadroparin (n ¼ 6) and control (n ¼ 9). (B)
Representative fibrillation electrograms. The unipolar fractionation index was lower in the treated compared with the untreated animals. (C) Endo-
mysial fibrosis quantified as cell–cell distances in the epicardial layer of the atrial wall. In the nadroparin-treated group, less atrial fibrillation-related
atrial fibrosis was present. (D) Nadroparin-treated animals showed reduced numbers ofa-smooth muscle actin-positive myofibroblasts (right staining
panel) compared with controls (left panel). (E) A trend towards a reduced matrix metalloproteinase-1/ tissue inhibitor of matrix metalloproteinase-1
ratio in an animals treated with nadroparin (P ¼ 0.0212 for difference between combined left and right atria for untreated vs. treated). Representative
immunohistochemical staining for matrix metalloproteinase-1 in the right atria of a control (left) and an anticoagulated (right) goat. *P, 0.05 nadro-
parin vs. control.
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model. Atrial fibrillation goats treated with nadroparin, which low-
ers Factor Xa-mediated thrombin generation and thus PAR activa-
tion, showed lower AF complexity and less AF-related fibrosis.
These observations are particularly interesting as NOACs have
been demonstrated to effectively inhibit PAR stimulation. Future
studies will have to address the question whether hypercoagulability
is also associated with progression of atrial remodelling in patents
with AF and whether anticoagulants can also effectively prevent at-
rial fibrosis in these patients.
Limitations
Fibroblasts in culture differentiate rapidly into myofibroblasts.39,40
For this reason, we used fibroblasts from a low passage. As ex-
pected, a large part of our cells expressed smooth muscle actin, sug-
gesting the myofibroblasts phenotype. Nevertheless, thrombin
exposure could clearly accentuate the myofibroblast phenotype
even further and provoke pro-inflammatory and pro-fibrotic
responses.
We used nadroparin treatment in the goats as its effect on the co-
agulation system is well known and can accurately be monitored.
The use of dabigatran for direct thrombin inhibition in the in vitro
model and nadroparin for inhibition of both thrombin and Factor
Xa in the in vivo goat model can be considered as a limitation of
the study. Since the pharmacodynamics of direct thrombin or Factor
Xa inhibitors in goats are not fully known, we used parenteral inhib-
ition of coagulation with low molecular weight heparin. Also, the
protective effect of NOACs in other paradigms of AF, e.g. heart
failure-induced atrial remodelling, should be addressed. Further
studies will have to establish an effect of NOACs on the atrial re-
modelling process in animal models of different types of AF and in
patients with AF or with a high susceptibility to AF.
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